Publication date: Apr 11, 2019
(MENAFN – ACCESSWIRE ) The collaboration leverages Indivumed’s true multi-omics cancer database “IndivuType” and Evotec’s drug discovery platforms to identify new therapeutics for colorectal cancer HAMBURG, GERMANY / ACCESSWIRE / April 11, 2019 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH announced today that they have entered into a research collaboration to discover and develop first-in-class therapeutics for the treatment of colorectal cancer (“CRC”).
The collaboration, which runs for an initial term of two years, will combine Evotec’s proprietary bioinformatics analysis platform “PanHunter” as well as its small molecule and antibody discovery platforms with the CRC cohort of Indivumed’s true multi-omics cancer database “IndivuType”.
Indivumed’s commitment to generating high quality and extensive cancer patient data is synergistic to Evotec’s expertise in analysing multi-omics data and developing novel platforms to aid the discovery of first-in-class clearly differentiated small molecule and antibody therapeutics.
Under the terms of the agreement, Evotec has made an undisclosed upfront payment to Indivumed for access to the CRC patient cohort of the IndivuType database.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: “Evotec is very pleased to partner with Indivumed, who is truly dedicated to developing precision medicine in oncology by generating the most comprehensive multi-omics patient database in oncology that is differentiated from previous datasets due to the higher patient numbers and the application of rigorous quality standards.
Prof. Dr Hartmut Juhl, Chief Executive Officer of Indivumed, said: “IndivuType is the only true multi-omics database available in the world, enabling break-through insights that lead to new cancer solutions.
Our partnership with Evotec fits well with realising our vision of using the multi-omics data within IndivuType to generate new precision medicine therapeutics.
About IndivuType IndivuType, the world’s first true multi-omics database for individualised cancer therapy uses the highest quality cancer biospecimens that ultimately produces highest quality data to enable novel discoveries in cancer biology in the post-genomics era.